Patterns of Care in Medical Oncology
Which adjuvant endocrine therapy would you recommend initially for a woman with the following tumor?
Which adjuvant endocrine therapy would you recommend initially for a woman with the following tumor?
Which adjuvant endocrine therapy would you recommend initially for a woman with the following tumor?
When you use an aromatase inhibitor for breast cancer patients in each of the following settings, which aromatase inhibitor do you generally utilize?
When you use an aromatase inhibitor for breast cancer patients in each of the following settings, which aromatase inhibitor do you generally utilize?
When you use an aromatase inhibitor for breast cancer patients in each of the following settings, which aromatase inhibitor do you generally utilize?
How would you manage the therapy of this patient?
What percentage of your breast cancer patients on adjuvant aromatase inhibitors have significant arthralgias?
What percentage of your breast cancer patients on adjuvant aromatase inhibitors have significant arthralgias to the point that you consider discontinuing or switching agents?
What percentage of the breast cancer patients you start on tamoxifen have significant vasomotor symptoms to the point that you consider interventions such as SSRI antidepressants?
How would you manage the therapy at the following timepoints?
How would you manage the therapy at the following timepoints?
How would you manage the therapy at the following timepoints?
How do you generally approach management of patients who have just completed five years of an AI?
Which systemic therapy, if any, would you most likely recommend to a breast cancer patient with the following characteristics?
Which systemic therapy, if any, would you most likely recommend to a breast cancer patient with the following characteristics?
Which systemic therapy, if any, would you most likely recommend to a breast cancer patient with the following characteristics?
Which systemic therapy, if any, would you most likely recommend to a breast cancer patient with the following characteristics?
Aromatase inhibitors as monotherapy are reasonable treatment options for actively menstruating patients.
Does HER2 status influence your decision-making about utilizing an aromatase inhibitor in the adjuvant setting?
Does PR status influence your decision-making about utilizing an aromatase inhibitor in the adjuvant setting?
